Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28452088 | 0.95 | MAPT (0.38) | MAPTKDM4ECYP1A2HIF1AALDH1A1 | |
| Hexane SCHEMBL28194938 | 0.91 | DNTT (0.39) | MAPTKDM4EALDH1A1TSHRPOLB | |
| SCHEMBL1958200 | 0.85 | ALDH1A1 (0.46) | MAPTKDM4ECYP1A2HIF1AALDH1A1 | |
| SCHEMBL21618277 | 0.85 | ALDH1A1 (0.46) | MAPTKDM4ECYP1A2HIF1AALDH1A1 | |
| SCHEMBL855129 | 0.81 | ALDH1A1 (0.45) | MAPTKDM4EHIF1AALDH1A1TSHR | |
| SCHEMBL26359463 | 0.81 | ALDH1A1 (0.39) | MAPTKDM4ECYP1A2HIF1AALDH1A1 | |
| SCHEMBL2083091 | 0.79 | MAPT (0.39) | MAPTKDM4EHIF1AALDH1A1TSHR | |
| SCHEMBL19839277 | 0.79 | CYP1A2 (0.35) | MAPTKDM4ECYP1A2HIF1AALDH1A1 | |
| SCHEMBL29328854 | 0.79 | CYP1A2 (0.35) | MAPTKDM4ECYP1A2HIF1AALDH1A1 | |
| SCHEMBL29328852 | 0.78 | KDM4E (0.35) | MAPTKDM4ECYP1A2HIF1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108059599-B | Preparation method of Venetong key intermediate | 凯方医药科技（上海）有限公司 | 2020-08-21 | — | — | CN | claimed |
| CN-108059599-A | A kind of preparation method of Wei Naituoke key intermediates | 凯方医药科技（上海）有限公司 | 2018-05-22 | — | — | CN | claimed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250340550-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2024-02-08 | — | — | US | disclosed |
| EP-2435432-B3 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE IRELAND UNLIMITED CO (BM) | 2023-10-25 | — | — | EP | disclosed |
| EP-1913003-A1 | NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2008-04-23 | — | — | EP | disclosed |
| EP-1888550-A2 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2008-02-20 | — | — | EP | disclosed |
| CN-101068816-A | Novel thienopyridinepyrimidine derivatives | ALMIRALL LAB S A (ES) | 2007-11-07 | — | — | CN | disclosed |
| EP-1819710-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2007-08-22 | — | — | EP | disclosed |
| WO-2007040650-A9 | APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007040650-A2 | APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007017078-A1 | NEW PYRIDO[3',2':4,5]FURO[3,2-d]PYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-02-15 | — | — | WO | disclosed |
| US-20070027135-A1 | N-acylsulfonamides; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide | ABBVIE INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2006058724-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340550-A1 | SALTS AND CRYSTALLINE FORMS OF AN APOPTOSIS-INDUCING AGENT | BCL2, BAD, BAX | MAPT 823/4885KDM4E 2358/4885CYP1A2 4275/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | MAPT 4348/4885KDM4E 2177/4885CYP1A2 4591/4885 |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | MAPT 3890/4885KDM4E 3590/4885CYP1A2 4466/4885 |
| US-20070027135-A1 | N-acylsulfonamides; BCL-X1 protein inhibitors; anticarcinogenic agents; bladder cancer; N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide | BAX, BCL2L1, BCL2A1 | MAPT 3953/4885KDM4E 308/4885CYP1A2 4780/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAPT 3890/4885KDM4E 3590/4885CYP1A2 4466/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | MAPT 3062/4885KDM4E 3692/4885CYP1A2 3365/4885 |
| US-20240043404-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | MAPT 3890/4885KDM4E 3590/4885CYP1A2 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.